Prolor reports success in extended growth hormone trial

The four-month extended Phase II clinical trial of its long-acting human growth hormone (validates the earlier results of the one-month clinical trial.

Prolor Biotech Inc. (AMEX: PBTH; TASE: PBTH) today reported that the four-month extended Phase II clinical trial of its long-acting human growth hormone (hGH-CTP) validates the earlier results of the clinical trial, in which hGH-CTP was injected in growth hormone deficient adults once a week over one month. The new study reaffirmed that once a week dosages can replace even consecutive daily injections of currently marketed human growth hormone.

The four-month extended study enrolled 42 growth hormone deficient adults (34 men and eight women) who had received a daily growth hormone therapy and who had previously participated in the Phase II trial that tested a once-weekly hGH-CTP regimen or in the pilot assessment of a twice-monthly hGH-CTP regimen.

Preliminary analysis of the extended study's data also confirmed the safety and tolerability of hGH-CTP, with no unexpected adverse events. In addition, there was no indication that high doses of hGH-CTP can induce excessive levels of insulin-like growth factor 1 (IGF-1) above the normal range. The study found that the proportion of patients receiving once-weekly injections of hGH-CTP who achieved the normal range of IGF-1 levels was comparable with the proportion of patients who received daily dosages of commercial growth hormones.

Prolor's share price rose 1.5% by mid-afternoon on the TASE following the announcement to NIS 20.13, after falling 1.9% yesterday on Nasdaq to $5.24, giving a market cap of $290 million.

Published by Globes [online], Israel business news - - on May 7, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017